Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.
The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes with 96% confidence.¹
Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).
Helen Ljungdahl Round
President and CEO
+46 73 077 02 83
+1 267 809 1225